No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
AU Stock MarketDetailed Quotes
VBLD Vanguard Global Infrastructure ETF
- 62.740
- +0.620+1.00%
20min DelayMarket Closed Jun 28 15:51 AET
62.740High62.380Low
62.740High62.380Low8.11KVolume62.680Open62.120Pre Close507.92KTurnover66.96652wk High0.15%Turnover Ratio5.38MShares55.97852wk Low--EPS TTM337.78MFloat Cap66.966Historical High--P/E (Static)5.38MShs Float42.212Historical Low--EPS LYR0.58%Amplitude1.85Dividend TTM--P/B1Lot Size2.95%Div YieldTTM
Intraday
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
First Solar, Clean Energy Stocks Slump After Biden-Trump Debate
Utility Stocks Outperform: 2 Standouts Deliver Impressive Returns In 2024
While the broader market had its ups and downs in the first half of 2024, two utility stocks have defied expectations, delivering stellar returns and significantly outpacing their peers. The Utility s
Wells Fargo Updated Its Signature Picks, With Vertex Pharma and AvalonBay as Adds
NextEra Energy Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/27/2024 13.79% Citigroup $69 → $84 Maintains Buy 06/20/2024 21.92% JP Morgan $76 → $90 Maintains Overwe
U.S. Weekly Rail Traffic Rises 3.6% Year-over-year
$100 Invested In This Stock 15 Years Ago Would Be Worth $800 Today
Union Pacific (NYSE:UNP) has outperformed the market over the past 15 years by 2.84% on an annualized basis producing an average annual return of 15.59%. Currently, Union Pacific has a market capitali
Comments
The trial of VB-601 may add value but hiring an advisor for strategic options and reporting losses indicate resource pressure and strategy shift, thus casting doubt on future performance.
Press Release: VBL Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateMatthew Trudeau's appointment as CCO massively benefits VBL, given his extensive experience in leading commercial practices at different biotech firms. His expertise is expected to be crucial in preparing for the anticipated OVAL Phase 3 trial readout in the second half of 2022.
EIC Accelerator funds VBL as it approaches the final enrollment phase of its key product candidate, ofra-vec (VB-111), for ovarian cancer. The CEO perceives this investment as acknowledgment of the potential ofra-vec offers to patients and the current critical need in ovarian cancer therapies.
Read more